Skip to main content
Fig. 1 | Trials

Fig. 1

From: Protocol for a randomised controlled feasibility study examining the efficacy of brief cognitive therapy for the Treatment of Anxiety Disorders in Adolescents (TAD-A)

Fig. 1

Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) schedule of enrollment, interventions and assessments. ACTA Adolescent Cognitive Treatment for Anxiety, ADIS-c/p Anxiety Disorder Interview Schedule for Diagnostic and Statistical Manual of Mental Disorders, Version 4. (DSM-IV) child and parent version, KSADS-c/p Kiddie Schedule for Affective Disorders and Schizophrenia – child and parent version, CGI-I Clinical Global Impression-Improvement, RCADS-c/p Revised Child Anxiety and Depression Scale – child and parent versions, CAIS-c/p Child Anxiety Impact Scale – child and parent version, ORS Outcome Rating Scale, SRS Session Rating Scale, ACTA-only disorder-specific measures Cognitive questionnaires (Social Anxiety Disorder = Child & Adolescent Social Cognitions Questionnaire; Generalised Anxiety Disorder = Metacognitions Questionnaire for Children; Specific Phobia (including vomit phobia) = Phobia Beliefs Questionnaire; Panic Disorder = Agoraphobia Cognitions Questionnaire), Safety Behaviour questionnaires (Social Anxiety Disorder = Social Behaviours Questionnaire; Generalised Anxiety Disorder = Worry Behaviour Inventory; Specific Phobia (including vomit phobia) and Panic Disorder = Safety Seeking Behaviours Questionnaire), Symptom measures (Social Anxiety Disorder = Liebowitz Social Anxiety Scale; Generalised Anxiety Disorder = Penn State Worry Questionnaire; Specific Phobia = Specific Phobia – Interference and Avoidance Questions, Specific Phobia of Vomiting = Specific Phobia of Vomiting Inventory; Panic Disorder = Panic Disorder Severity Scale), ESQ Experience of Service Questionnaire, CSRI Client Services Receipt Inventory, EQ5D EuroQol (Quality of Life), CHU-9D Child Health Utility (Paediatric Quality of Life), *Qualitative interviews will take place on the same day as the booster session or at another time between the finishing treatment and the 3-month follow-up

Back to article page